EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Physiologically based pharmacokinetic modeling of tafenoquine and evaluation of transporter-mediated drug–drug interactions

Luisa Oliveira Santos, Pieter Annaert, Francine Johansson Azeredo

Frontiers in Pharmacology · 17.07.2026 · 17

DOI: 10.3389/fphar.2026.1880776 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 17.07.2026. Verfasst von Luisa Oliveira Santos und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pharmacokinetics and Pharmacometrics, Faculty of Pharmacy, Federal University of Bahia, Salvador, Brazil. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The aim of the study was to develop a physiologically based pharmacokinetic (PBPK) model of tafenoquine (TQ), a new drug for the radical cure of Plasmodium vivax malaria and assess drug-drug interactions with substrates of the transporters OCT2 and MATE1.

Methods

A whole-body PBPK model was built using PK-Sim® to simulate 100 adults aged 19–53 years weighing 51–108 kg. Hepatic clearance was incorporated into the model. Literature data on the oral administration of TQ were used to verify the model. The qualified model was used to simulate co-administration with metformin (MTF), an OCT2 and MATE1 substrate, and assess drug-drug interactions. Results and Discussion The PBPK model presented a good descriptive and predictive performance for plasma concentration-time profiles. Quantitative measures of the model performance fell within the 2-fold acceptance criteria when predictions were compared to observed values. Co-administration of TQ with MTF presented no alteration of MTF’s exposure. Model simulations suggest that there is no significant interaction between TQ and substrates of OCT2/MATE1, such as MTF.

Schlagwörter

Stichwörter der Autor:innen

drug-drug interactions (DDI)malariapharmacometricsphysiologically based pharmacokinetic (PBPK) modelingtafenoquine

Autor:innen und Institutionen

  • Laboratory of Pharmacokinetics and Pharmacometrics, Faculty of Pharmacy, Federal University of Bahia, Salvador, Brazil.
  • Drug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
  • BioNotus, Niel, Belgium.
  • Center for Pharmacometrics & System Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, United States.

Zitieren

APA

Santos, L. O., Annaert, P., & Johansson Azeredo, F. (2026). Physiologically based pharmacokinetic modeling of tafenoquine and evaluation of transporter-mediated drug–drug interactions. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1880776

Vancouver

Santos LO, Annaert P, Johansson Azeredo F. Physiologically based pharmacokinetic modeling of tafenoquine and evaluation of transporter-mediated drug–drug interactions. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1880776

BibTeX
@article{Santos2026,
  author = {Santos, Luisa Oliveira and Annaert, Pieter and Johansson Azeredo, Francine},
  title = {Physiologically based pharmacokinetic modeling of tafenoquine and evaluation of transporter-mediated drug–drug interactions},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1880776}
}
Kostenlos starten →